Logo
x

Search

Subscribe Now

UC

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis

  • July 12, 2021
AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

AbbVie Report Results of Rinvoq (upadacitinib) in P-III Maintenance Study for the Treatment of Ulcerative Colitis

  • June 30, 2021
Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligi...

  • May 21, 2021
Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Cancer (UC)

Roche and Basilea Sign a Research Collaboration to Evaluate Derazantinib + Tecentriq (atezolizumab) in Patients with Urothelial Ca...

  • January 25, 2019
Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severely Active Ulcerative Colitis (UC)

Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severe...

  • January 9, 2019
Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

Sandoz's Hymiroz (adalimumab-adaz) Receives the US FDA Approval for Treatment of Chronic Autoimmune Diseases

  • October 31, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.